[Use of the monopeak insulin drugs "insulrap" and "insulong" in the treatment of type I diabetes mellitus].
A study was made of the effectiveness of the use of new monopeak insulin drugs of short-term and prolonged action in therapy of 30 patients with type 1 diabetes mellitus. The effect of the drugs was estimated during a follow-up (1-6 mos.) by the parameters of carbohydrate metabolism and the time course of serum insulin binding capacity as well as by change in a dose of insulin as compared to that of the common Soviet drugs of the insulin-zink-suspension (IZS) group and monopeak drugs of the Long group. The drugs under study were shown to be no inferior to the monopeak drugs of the Long group and in some cases superior to the drugs of the IZS group. A significant decrease in the titer of antibodies to insulin against a background of therapy was unnoticed. Positive and negative qualities of both drugs (Insulrap and Insulong) were discussed.